BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
22 mars 2018 12h00 HE
|
Idera Pharmaceuticals, Inc.; BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., March 22, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (“BioCryst”) (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA),...
Idera Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update
07 mars 2018 07h30 HE
|
Idera Pharmaceuticals, Inc.
EXTON, Pa. and CAMBRIDGE, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery,...
Idera Pharmaceuticals Announces Launch of Global Phase 3 Trial Evaluating IMO-2125 in Combination with Ipilimumab for the Treatment of Anti-PD-1 Refractory Melanoma (ILLUMINATE 301)
01 mars 2018 07h00 HE
|
Idera Pharmaceuticals, Inc.
EXTON, Pa. and CAMBRIDGE, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming Healthcare Investor Conferences
19 févr. 2018 13h00 HE
|
Idera Pharmaceuticals, Inc.; BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., Feb. 19, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), today announced they will...
BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More Patients with Rare Diseases
22 janv. 2018 08h30 HE
|
Idera Pharmaceuticals, Inc.; BioCryst Pharmaceuticals, Inc.
Filed by BioCryst Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12Under the Securities Exchange Act of 1934Subject Company: Idera...
Idera Pharmaceuticals Provides 2018 Update and Outlook
05 janv. 2018 07h00 HE
|
Idera Pharmaceuticals, Inc.
EXTON, Pa. and CAMBRIDGE, Mass., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and...
U.S. FDA Grants Fast Track Designation for Idera Pharmaceuticals’ IMO-2125 in Combination with Ipilimumab for Treatment of PD-1 Refractory Metastatic Melanoma
29 nov. 2017 07h30 HE
|
Idera Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and EXTON, Pa., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
Idera to Present at the 29th Annual Piper Jaffray Healthcare Conference
27 nov. 2017 16h01 HE
|
Idera Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and EXTON, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
Idera Pharmaceuticals Presents Positive Translational and Clinical Data Update from Ongoing IMO-2125 Development Program at the 2017 Society for Immunotherapy of Cancer Annual Meeting (SITC)
09 nov. 2017 07h30 HE
|
Idera Pharmaceuticals, Inc.
- Available Translational Data Continue to Demonstrate Correlation between Proliferation and Clonal Expansion of T-Cells to Clinical Responses - - An additional 5th Unconfirmed RECIST v1.1 Response...
Idera Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
06 nov. 2017 16h02 HE
|
Idera Pharmaceuticals, Inc.
– IMO 2125 Translational Data Update at SITC on November 11 –– Completes Public Offering, extends runway into second quarter 2019 – CAMBRIDGE, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Idera...